NPG-2044 is under clinical development by Novita Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NPG-2044’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NPG-2044 overview

NPG-2044 is under development for the treatment of solid tumors including  ovarian cancer, endometrial cancer, uterine cancer, fallopian tube cancer, cervical cancer, vulvar cancer, vaginal cancer and triple-negative breast cancer. It is a small molecule administered through oral route. It acts by targeting fascin protien. It is a new molecular entity (NME).

It was under development for the treatment of  colon cancer, esophageal cancer, lymphoma, metastatic breast cancer, metastatic pancreatic cancer, metastatic prostate cancer, metastatic lung cancer, metastatic liver cancer, metastatic ovarian cancer.

Novita Pharmaceuticals overview

Novita Pharmaceuticals, is a developer of therapeutic drugs for the treatment of cancer. The company is headquartered in United States.

For a complete picture of NPG-2044’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.